Marty Munson, currently the health director of Men's Health, has been a health editor at properties including Marie Claire, Prevention, Shape and RealAge
Demand for weight-loss drugs Americans have only modest expectations that the new weight-loss drugs formally known as glucagon-like peptide-1 (GLP-1) receptor agonists will reduce obesity in the U.S., according to the Centers new survey
But every once in a while, a drug comes to the market that changes the landscape in the treatment of obesity
There are over 200 types of cancer, including breast cancer, lung cancer, skin cancer, prostate cancer, colon cancer, and lymphoma
Tirzepatide activates GLP-1 and GIP receptors systemically, but localized reactions at the injection site are distinct and relate to mechanical or chemical irritation rather than the drug's mechanism